Evidence map›Paper›PMID 23257289›Full record

ArticleHuman molecular genetics2013

RNA-binding ability of FUS regulates neurodegeneration, cytoplasmic mislocalization and incorporation into stress granules associated with FUS carrying ALS-linked mutations.

J Gavin Daigle, Nicholas A Lanson, Rebecca B Smith, Ian Casci, Astha Maltare, John Monaghan, Charles D Nichols, Dmitri Kryndushkin, Frank Shewmaker, Udai Bhan Pandey

Open access · bronzeAbstract read
In one paragraph

Article in Human molecular genetics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 130 papers.

0numbers the graph read from it
0cells of the map it votes in
130citing papers in PubMed
9.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

130 citing papers in PubMed, 209 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

70 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

J Gavin DaigleDepartment of Genetics, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
Nicholas A Lanson
Rebecca B Smith
Ian Casci
Astha Maltare
John Monaghan
Charles D Nichols
Dmitri Kryndushkin
Frank Shewmaker
Udai Bhan Pandey
Pediatrics and Genetics · USUniformed Services University of the Health Sciences · USLouisiana State University Health Sciences Center New Orleans · USSt. Jude Children's Research Hospital · US

Funding

Multiphoton ConfocalP30GM103340 · NIGMS · LSU HEALTH SCIENCES CENTER · PI BAZAN, NICOLAS G. · 2012 to 2016
$5.1M
NIGMS NIH HHS 1P30GM103340-01A1
6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS) is an uncommon neurodegenerative disease caused by degeneration of upper and lower motor neurons. Several genes, including SOD1, TDP-43, FUS, Ubiquilin 2, C9orf72 and Profilin 1, have been linked with the sporadic and familiar forms of ALS. FUS is a DNA/RNA-binding protein (RBP) that forms cytoplasmic inclusions in ALS and frontotemporal lobular degeneration (FTLD) patients' brains and spinal cords. However, it is unknown whether the RNA-binding ability of FUS is required for causing ALS pathogenesis. Here, we exploited a Drosophila model of ALS and neuronal cell lines to elucidate the role of the RNA-binding ability of FUS in regulating FUS-mediated toxicity, cytoplasmic mislocalization and incorporation into stress granules (SGs). To determine the role of the RNA-binding ability of FUS in ALS, we mutated FUS RNA-binding sites (F305L, F341L, F359L, F368L) and generated RNA-binding-incompetent FUS mutants with and without ALS-causing mutations (R518K or R521C). We found that mutating the aforementioned four phenylalanine (F) amino acids to leucines (L) (4F-L) eliminates FUS RNA binding. We observed that these RNA-binding mutations block neurodegenerative phenotypes seen in the fly brains, eyes and motor neurons compared with the expression of RNA-binding-competent FUS carrying ALS-causing mutations. Interestingly, RNA-binding-deficient FUS strongly localized to the nucleus of Drosophila motor neurons and mammalian neuronal cells, whereas FUS carrying ALS-linked mutations was distributed to the nucleus and cytoplasm. Importantly, we determined that incorporation of mutant FUS into the SG compartment is dependent on the RNA-binding ability of FUS. In summary, we demonstrate that the RNA-binding ability of FUS is essential for the neurodegenerative phenotype in vivo of mutant FUS (either through direct contact with RNA or through interactions with other RBPs).

Indexed as

Mutation, MissenseAmino Acid MotifsAmyotrophic Lateral SclerosisAnimalsCell NucleusCytoplasmDisease Models, AnimalDrosophilaDrosophila ProteinsHeterogeneous-Nuclear Ribonucleoprotein Group F-HHumansInclusion BodiesMotor NeuronsProtein TransportRNA-Binding Protein FUSDrosophila ProteinsFUS protein, DrosophilaHeterogeneous-Nuclear Ribonucleoprotein Group F-HRNA-Binding Protein FUS

Identifiers

PMID23257289
PMCPMC3578413
OpenAlexW2101847306

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.